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Abstract 
Review on LRP1B, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: LRP-DIT, LRPDIT 
HGNC (Hugo): LRP1B 
 
Location: 2q22.1 
Local order: Centromere ... - HNMT - SPOPL - 
NXPH2 - LRP1B - KYNU - ARHGAP15 - GTDC1 - 
ZEB - ... qter 
Note 
LRP1B is encoded in the long arm of chromosome 2, 
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DNA diagram. Overview of sequence-related elements in the LRP1B gene. The gene comprises 91 exons, an upstream CpG-
enriched region, an element for the P300 transcription factor (within intron 1) and a downstream 3' UTR sequence which encodes a 




LRP1B genomic sequence spans 1.9 Mbs, with a 
genetic structure composed of 91 exons that comprise 
16.5 Kbs of coding sequence (Liu et al., 2000b). Intron 
1 is very large and contains a functionally validated 
binding site for the P300 Histone Acetyltransferase 
transcription factor (Prazeres et al., 2011). A CpG 
enriched region spans the 5' UTR, exon 1 and upstream 
sequence of intron 1 (Sonoda et al., 2004; Prazeres et 
al., 2011). The 3' UTR encodes sequences that are 
several predicted microRNA binding sites. Functional 
studies validated binding of miR-548a-5p (Prazeres et 
al., 2011). 
Transcription 
Expression is epigenetically regulated, both by DNA 
methylation and presumably by histone modification. 
This comes from finding of promoter hypermethylation 
in several types of cancer (Sonoda et al., 2004; 
Nakagawa et al., 2006; Rahmatpanah et al., 2006; 
Taylor et al., 2007a; Taylor et al., 2007b; Lu et al., 
2010) with demethylation agents such as 5-azacytidine 
or siRNA for DNMT1 results in LRP1B re-expression 
(Sonoda et al., 2004; Prazeres et al., 2011). Also, 
treatment with Histone Deacetylase Inhibitors, such as 
Tricostatin A, induces expression of LRP1B (Sonoda et 
al., 2004; Prazeres et al., 2011). 
Transcripts with alternative C-terminal result from  
alternative splicing of exon 90, which impact 
differential binding of partners interacting with the 
cytoplasmic domain of LRP1B (Shiroshima et al., 
2009). 
Pseudogene 
No LRP1B pseudogene is annotated. 
Protein 
Description 
Like other members of the LDL receptor family, the 
modular structures within LRP1B include an 
extracellular region with interspersed cysteine-rich 
complement-type repeats (CRs) and EGF repeats with 
β-propeller structure, a transmembrane domain and a 
cytoplasmic domain with endocytosis NPXY motifs. In 
what concerns the specific structure of LRP1B, it has 
four putative ligand-binding clusters (I, II, III, and IV, 
from the amino terminus) that consist of 2, 8, 10, and 
12 CRs, respectively. These domain clusters are 
separated from one another by three clusters of EGF 
precursor repeats and (F/Y) WXD spacer repeats. 
LRP1B contains a putative furin endopeptidase 
processing site (REKR) at positions 3954-3957 
(Willnow et al., 1999). This post-translational 
processing event results in the formation of mature 
LRP as a noncovalently associated heterodimer, 
consisting of an extracellular 515-kDa subunit and a 
transmembrane 85-kDa subunit.  
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Protein diagram. LRP1B is composed of modular domains, namely extracellular cysteine ligand-binding repeats (CRs) and epidermal 
growth factor precursor-like domains with β-propeller structure, single pass transmembrane region and cytoplasmatic domains with 
endocytosis NPXY motifs that are nonetheless homologous to other LDL Receptor Family members, for which the prototypic member is 
the LDL Receptor. The specificity in LRP1B structure comes from the number and organization of these modules. 
 
The transmembrane domain of LRP1B is separated 
from domain IV and by a cassette of six epidermal 
growth factor-like precursor repeats. The cytoplasmic 
tail of LRP1B contains two NPXY motifs. Between 
these two, there is a unique insertion of 33 amino acid 
residues contributed by exon 90 (Willnow et al., 1999). 
Expression 
LRP1B is expressed at higher levels in the central 
nervous system, thyroid, skeletal muscle and testis. In 
other organs lower expression levels are detected (Haas 
et al., 2011). 
Localisation 
LRP1B expression localizes to the cell membrane as 
well as to several categories of membrane vesicles 
involved in intracellular traffic. Proteomic analysis has 
also detected LRP1B in extracellular vesicles, namely 
as a component of exosomes (Looze et al., 2009). 
Soluble LRP1B ectodomains may be released to the 
extracellular milieu through the action of shedases and 
exert anchorage independent functions (Dietrich et al., 
2010). 
Function 
The modular protein domains of Lipoprotein Receptors 
(LRs) account for three important properties. First, 
individual LRs have been shown to recognize multiple 
(more then 30) structurally unrelated extracellular 
ligands, that include lipoprotein complexes but also 
many other categories of molecules. Second, LRs are 
capable of engaging endocytosis, resulting in clearance 
of their ligands from the extracellular milieu. Third, 
LRs can associate with other membrane bound 
receptors, such as integrins and receptor tyrosine 
kinases, and with intracellular signaling molecules. The 
classical roles of LRPs are to act as scavenger receptors 
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in the clearance of a myriad of extracellular ligands 
from the pericellular environment (Herz and 
Strickland, 2001; May et al., 2007). The best studied 
ligands of LRs include lipoprotein complexes and 
proteinase/proteinase inhibitor complexes, such as α2 
macroglobulin and members of the urokinase 
Plasminogen Activating (uPA) system (uPA, uPAR 
and PAI-1) (Herz et al., 1992; Nykjaer et al., 1992). 
LRP1B functions at the extracellular and cell 
membrane levels: 
In order to characterize LRP1B ligands, immobilized 
recombinant extracellular sub-domains of LRP1B have 
been used as decoys to perform affinity 
chromatography using brain lysates (Liu et al., 2001) 
or in serum (Haas et al., 2011) as a source of potential 
physiological ligands. Using this strategy, LRP1B has 
been previously found to bind lipoproteins and ligands 
of the uPA system (Liu et al., 2001; Li et al., 2002; 
Knisely et al., 2007). Also several serum proteins, 
including fibrinogen and apoE-carrying lipoproteins 
showed affinity to LRP1B extracellular regions (Haas 
et al., 2011).  
It should nevertheless be noted that these approaches 
inherently under-estimate the full impact of LRP1B 
activity since, in the former study (Liu et al., 2001), the 
proteome which has been interrogated was derived 
from brain-lysate fractions, rather than the extracellular 
proteome which shares the physiological milieu with 
LRP1B. In the latter study (Haas et al., 2011), the use 
of serum restricts candidate ligands to systemic 
circulating factors and neglects local factors that may 
play a role in the tissue microenvironment. Evidence 
that LRP1B activity may, directly or indirectly, 
modulate the abundance of multiple extracellular 
factors comes from the analysis of conditioned media 
from LRP1B overexpressing cells, relative to their 
parental counterparts. Conditioned media from cells 
overexpressing LRP1B shows a reduction in the 
amounts of MMP2 as well as other metalloproteinases, 
growth factors, cytokines and angiogenic factors, 
indicating that LRP1B impacts the overall extracellular 
proteome (Prazeres et al., 2011).  
It is thus expected that LRP1B, in analogy with other 
LRs, can displays a myriad of additional extracellular 
ligands that impact the physiology in the extracellular 
microenvironment. 
LRP1B ligands also include the cellular prion protein 
(Taylor and Hooper, 2007; Lu et al., 2010). 
At the membrane level, LRP1B has been shown to 
modulate the localization of Urokinase and PDGF 
receptors (Tanaga et al., 2004) and to retain beta-
amyloid precursor protein at the cell surface and 
reducing amyloid-beta peptide production (Cam et al., 
2004). 
Intracellular LRP1B partners: 
Six interacting partners of the LRP1B cytoplasmic 
region have been identified by yeast two-hybrid screen 
and immunoprecipitation.  
One of the partners, PICK1 recognizes the C-terminus 
of LRP1B and inhibits phosphorylation of LRP1B by 
PKC alpha (Shiroshima et al., 2009). The output of 
these interactions in terms of signaling pathways 
activated in consequence of LRP1B activity remains 
unexplored. 
Proteolytic release of LRP1B domains: 
LRP1B ectodomains resulting from proteolytic 
shedding of the extracellular region can be found in the 
soluble form (Dietrich et al., 2010). 
LRP1B has also been shown to undergo regulated 
intra-membrane proteolysis in a gamma-secretase-
dependent manner, releasing an intracellular domain 
(ICD) that then translocates to the nucleus (Liu et al., 
2007).  
The functions of the ICD in the nucleus are unknown. 
Functions associated with heterologous ligands: 
LRP1B may also act as a receptor for heterologous 
biomolecules such as the Pseudomonas exotoxin 
(Pastrana et al., 2005) and, most interestingly, for 
certain drugs, putting emphasis on the role of 
endocytosis in cellular drug uptake (Chung and Wasan, 
2004).  
In accordance with this, reduced uptake of liposomes 
by LRP1B may underlie the mechanism of acquired 
resistance to liposomal doxorubicin chemotherapy in 
high-grade serous ovarian cancers that display LRP1B 
deletion (Cowin et al., 2012). 
Homology 
LRP1B is a member of the LDL receptor family which 
is composed of seven receptors structurally 
homologous to the LDL receptor, the prototypic gene 
of familial hypercholesterolemia (Hobbs et al., 1992).  
These receptors, commonly known as lipoprotein 
receptors (LRs), include the LDL receptor, very low 
density lipoprotein (VLDL) receptor, apoE receptor 2, 
multiple epidermal growth factor-like domains 7 
(MEGF7), glycoprotein 330 (gp330/megalin/LRP2), 
LRP1 and LRP1B. In addition, the family includes 
members that are more distantly related, such as LRP5, 
LRP6 and SorLa/LRP11.  
The close similarity in protein domain structure 
between LRPs strongly suggests that Lipoprotein 
Receptors may share a comparable spectrum of 
ligands.  
Nevertheless, this deduction may not be 
straightforward.  
For instance, LRP1B ligands of the uPA system were 
found to overlap those of LRP1, its closest related 
member (Liu et al., 2001).  
However, distinct properties are displayed by LRP1B 
since, in contrast to LRP1, cells expressing LRP1B 
display a substantially slower rate of uPA/PAI-1 
complex internalization (Knisely et al., 2007), which 
impairs the regeneration of free uPAR on the cell 
surface and correlates with a diminished rate of cell 
migration (Liu et al., 2001; Li et al., 2002). This  
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emphasizes that the functions of LRs may be 
overlapping and yet distinct as a result of their ligand 
spectrum and kinetics of endocytosis (Liu et al., 2001). 
Mutations 
Germinal 
No germline LRP1B mutations have been 
characterized. 
Somatic 
The LRP1B gene was originally isolated by positional 
cloning on the basis of homozygous deletions (HD) 
detected in human lung cancer cell lines (Kohno et al., 
2010; Liu et al., 2000a; Liu et al., 2000b). In a 
genomic-wide screen, LRP1B was reported amongst 
the top 10 most significantly deleted genes across 3312 
human cancer specimens (Beroukhim et al., 2010).  
Mapping of focal deletions found in these cancer 
specimens are published at 
http://www.broadinstitute.org/tumorscape/pages/portal
Home.jsf. In individual studies of specific tumor types, 
LRP1B deletions have been reproducibly been 
observed in lung (Nagayama et al., 2007; Kohno et al., 
2010), esophagus (Sonoda et al., 2004), oral (Cengiz et 
al., 2007), breast (Kadota et al., 2010), renal (Langbein 
et al., 2002; Ni et al., 2013), neural (Roversi et al., 
2006; Yin et al., 2009), thyroid (Prazeres et al., 2011) 
and ovarian cancer (Chung and Wasan, 2004).  
Aside from deletions, LRP1B point mutations have 
been reported in a significant percentages of lung 
cancer (Ding et al., 2008) as well as in the sequencing 
of genomes derived from melanoma (Nikolaev et al., 
2011) and triple negative breast cancer (Craig et al., 
2013). 
Implicated in 
Cancer, across types 
Note 
The diversity of biological ligands underlies the role of 
LRs in multiple pathologic processes, that include 
atherosclerosis (Tanaga et al., 2004; Seki et al., 2005) 
Alzheimer's disease (Jaeger and Pietrzik, 2008; Lillis et 
al., 2008; Wagner and Pietrzik, 2012) and cancer, the 
focus of this description below. 
LRP1B, a member of the low-density lipoprotein 
(LDL) receptor family, was identified as a putative 
tumor suppressor. The down-expression of LRP1B was 
observed in multiple primary cancers. 
Oncogenesis 
The "signature" of LRP1B inactivation is archetypal of 
a tumor suppressor gene and reflects selection towards 
bi-allelic inactivation and complete abrogation of the 
gene function.  
In tumors, one can observe that multiple inactivation 
hits, of structural and regulatory nature, have taken 
place, on both alleles through diverse combinations of 
events such as genetic deletions (observable by 
homozygous deletion), accompanied by epigenetic 
silencing (DNA methylation), or sometimes by 
microRNA overexpression (Prazeres et al., 2011).  
The role of LRP1B as a tumor suppressor may result 
from modulation of cell migration and invasive 
capacity, through regulation of the urokinase 
plasminogen system (Liu et al., 2001). Cells expressing 
LRP1B display a substantially slower rate of uPA/PAI-
1 complex internalization (Knisely et al., 2007) which 
impairs the regeneration of unoccupied uPAR on the 
cell surface and correlates with a diminished rate of 
cell migration (Li et al., 2002; Tanaga et al., 2004). 
Aside from members of the plasminogen system, 
LRP1B expression has been shown to deplete the 
extracellular medium of MMP2 and other factors 
(Prazeres et al., 2011). These results support the 
hypothesis that LRP1B endocytosis may (directly or 
indirectly) constrain the abundance of critical factors in 
the tumor microenvironment. 
Lung cancer 
Note 
Nagayama, Kohno et al. (2007) have described that 
homozygous deletions (HD) was searched for in 43 
lung cancer cell lines. The gene LRP1B was also 
included among the genes. Fifty-one homozygous 
deletions regions containing 113 genes were identified. 
The LRP1B was the third most frequent targets of HD. 
All eight HD segments at the LRP1B gene locus 
detected in that study included its coding exons, 
consistent with previous reports (Liu et al., 2000a; 
Sonoda et al., 2004). At present, the pathogenic 
significance of LRP1B deletions is unclear; however, 
frequent HD in these loci indicates that the inactivation 
of this gene has major roles in the development of lung 
cancer. LRP1B was mapped at the fragile sites, 
FRA2F, FRA3B, and FRA16D, and had been found 
homozygously deleted in a subset of lung cancers (Liu 
et al., 2000a; Zöchbauer-Müller et al., 2000; Paige et 
al., 2001; Fabbri et al., 2005; Smith et al., 2006). 
Kohno, Otsuka et al. (2010) have verified homozygous 
deletions in 176 genes. They consisted of 171 protein-
encoding genes and five miRNA genes. These 176 
genes were located in 45 regions on 17 chromosomes. 
They included known tumor suppressor genes, as well 
as candidate tumor suppressor genes shown to be 
hemizygously or homozygously deleted in several 




The expression of LRP1B mRNA is frequently lost in 
esophageal squamous cell carcinoma (ESCs) as a 
consequence of either homozygous deletions or DNA 
methylation and the re-expression of this gene inhibits 
growth of ESC cells. These two types of events 
affecting the LRP1B gene may be useful as novel 
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diagnostic markers for ESC because of their high 
frequencies, although it remains unclear whether 
precancerous lesions of this tumor contain either of 
those alterations. The apparent multiplicity of tumor-
suppressing activities of LRP1B, however, suggests 
that this molecule might be a useful starting point for 




Genome-wide LOH analysis demonstrated high LOH 
ratio of 2q21-23 region by using the markers D2S1334 
and D2S1399 in head and neck cancer (Beder et al., 
2003). So far no other study showed frequent LOH of 
this region in oral cancer, but it has been suggested that 
at least one tumor suppressor gene exists at 2q21-24 
and involves in the carcinogenesis of various cancers 
including oral carcinoma. One candidate gene could be 
LRP1B, which has already been proposed to function 
as a tumor suppressor (Cengiz et al., 2007). 
Breast cancer 
Note 
Kadota, Yang et al. (2010) have observed intragenic 
deletions within several genes which potentially 
function as breast cancer tumor suppressor loci. These 
included deletions which disrupted LRP1B in 
MCF10CA1h and MCF10CA1a cell lines. 
Renal cancer 
Prognosis 
In urothelial cancer, only 8% of cases with Grade 1 and 
none with Grade 2 tumors showed loss of 
heterozygosity at the LRP1B gene, whereas 49% of the 
Grade 3 cases had allelic loss at the LRP1B genomic 
region, which can be taken to indicate that alteration of 
the LRP1B gene region is associated with high grade of 
urothelial cancer (Langbein et al., 2002). 
Oncogenesis 
Ni, Hu et al. (2013) have investigated the expression of 
LRP1B in Renal cell cancer (RCC) and its function on 
cell migration.  
They found that LRP1B mRNA was widely expressed 
in the normal renal tubular epithelial cells, but it was 
frequently down-expressed in RCC tissues and cell 
lines.  
The depletion of LRP1B increased the anchorage-
independent growth, cell migration and invasion in 
vitro. Moreover, the expression and activation of Rho 
family members, actin cytoskeletons and focal 
adhesions complex (FAC) were also affected, 
indicating that down-expression of LRP1B led to the 
increase of cell migration and invasion, which is 
possibly mediated by actin cytoskeleton remodeling, 
and expressional alteration of FAC components. At the 
same time, they also found that silencing of LRP1B 
obviously occurred in T1 of TNM. The result suggests 
that silencing of LRP1B is an early event in RCC. 
Their observation provided an insight into the potential 
contribution of LRP1B to tumorigenesis, and that 
LRP1B may be explored as a molecular target in RCC 
therapy by regulated epigenetic activation means.  
These functional specificities in cell spreading, 
migration and invasion strongly validated that LRP1B 
may function as a tumor suppressor, and exert opposite 




Data analysis of full-coverage chromosome 19 
highlighted two main regions of copynumber gain, 
never described before in gliomas, at 19p13.11 and 
19q13.13-13.2.  
Genomic hotspot detection facilitated the identification 
of small intervals resulting in positional candidate 
genes such as LRP1B (2q22.3) for losses, and other for 
gains.  
These data increase the current knowledge about 
cryptic genetic changes in gliomas and may facilitate 
the further identification of novel genetic elements, 
which may provide us with molecular tools for the 
improved diagnostics and therapeutic decision-making 
in these tumors (Roversi et al., 2006). 
LRP1B has been found frequently mutated in 
glioblastoma (GBM) (Roversi et al., 2006). A novel 
internal deletion of LRP1B was discovered in the U118 
GBM cell line and four GBM samples. Nucleotide 
sequencing of the LRP1B gene from U118 cells 
showed loss of exons 3 to 18 and an early stop codon, 
suggesting that the protein was no longer functional. 
This data suggest that LRP1B acts as a tumor 
suppressor gene in glioma cells and is aberrant in GBM 
(Yin et al., 2009). 
Thyroid cancer 
Note 
In non-medullary thyroid cancer, LRP1B under-
expression is significantly lower in highly aggressive 
undifferentiated thyroid tumors (Prazeres et al., 2011).  
LRP1B expression levels are significantly associated 
with vascular invasion in follicular thyroid cancer 
(Prazeres et al., 2011). 
Oncogenesis 
Prazeres, Torres et al. (2011) have shown that LRP1B 
inactivation (by chromosomal, epigenetic and 
microRNA (miR)-mediated mechanisms) resulted in 
changes to the tumor environment that confer cancer 
cells an increased growth and invasive capacity.  
Restoration of LRP1B impaired in vitro and in vivo 
tumor growth, inhibited cell invasion and led to a 
reduction of matrix metalloproteinase 2 in the 
extracellular medium.  
This emphasized the role of an endocytic receptor 
acting as a tumor suppressor by modulating the 
extracellular environment composition in a way that 
constrains the invasive behavior of the cancer cells. 
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Ovarian cancer 
Prognosis 
LRP1B binds to fibrinogen and apoE-containing 
ligands (Haas et al., 2011) and importantly, several 
studies have suggested that LDL receptor family 
members are involved in uptake of anionic liposomes 
and drugs (Chung and Wasan, 2004; Lakkaraju et al., 
2002).  
Due to high degree of intratumoral heterogeneity and 
the large number of chemotherapeutic agents 
commonly used in the relapse setting in high-grade 
serous cancer (HGSC) patients, the most common 
subtype of ovarian cancer, it is likely that there will be 
multiple mechanisms of acquired resistance. It was 
described that the deletion or downregulation of the 
lipid transporter LRP1B emerged as a significant 
correlate of acquired resistance. Functional studies 
showed that reducing LRP1B expression was sufficient 
to reduce the sensitivity of HGSC cell lines to 
liposomal doxorubicin, but not to doxorubicin, whereas 
LRP1B overexpression was sufficient to increase 
sensitivity to liposomal doxorubicin. These data 
indicates that LRP1B loss contributes to the emergence 
of resistance to chemotherapy, specifically to liposomal 
doxorubicin (Cowin et al., 2012). 
In conclusion, in high-grade serous ovarian cancers, 
LRP1B deletion is associated with worse prognosis as 
a result of acquired chemotherapy resistance to 
liposomal doxorubicin (Cowin et al., 2012). 
Alzheimer's disease 
Note 
Initially, LDL receptor gene family was of high interest 
due to its key function in cholesterol/apolipoprotein E 
(ApoE) uptake, with the e4 allele of ApoE as the 
strongest genetic risk factor for late-onset Alzheimer's 
disease (AD).  
In a review, Jaeger and Pietrzik (2008) have 
highlighted the involvement of different lipoprotein 
receptors in AD. Their functional implications reach 
from mediating amyloid precursor protein (APP) 
internalization, as LRP1B, intracellular trafficking, Aβ 
clearance out of the brain (LRP1) to an involvement in 
ApoE/cholesterol metabolism. These findings implicate 
an important role for lipoprotein receptors in the 
underlying mechanisms leading to the development of 
AD. These mechanisms will give way to new 
therapeutic strategies for the treatment of 
neurodegenerative diseases via interference with the 
role of lipoprotein receptors. 
Atherosclerosis 
Note 
Seki, Bujo et al. (2005) have characterized the 
functions of three groups of cultured smooth muscle 
cells (SMCs) with different origins in atherosclerotic  
arteries, in order to know a functional significance of 
LRP1B in the increased migration of SMCs. The  
results strongly suggest that LRP1B plays a role in the 
regulation of migration activity of SMCs through the 
modification of PDGF signals in the process of 
atherosclerosis. 
Tanaga, Bujo et al. (2004) have described that LRP1B 
modulates the catabolism of uPAR and PDGFR, 
affecting the migration of smooth muscle cells (SMCs).  
This functional characterization of LRP1B opens novel 
avenues for elucidating the (patho)physiological 
significance of SMC migration in atheromatous 
plaques. 
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